Active, not recruitingPhase 2NCT05695950
A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis
Studying Dermatomyositis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Galapagos NV
- Principal Investigator
- Galapagos Study DirectorGalapagos NV
- Intervention
- GLPG3667(drug)
- Enrollment
- 40 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2023 – 2026
Study locations (30)
- HonorHealth Neurology, Scottsdale, Arizona, United States
- Inland Rheumatology Clinical Trials, Inc., Upland, California, United States
- New Access Research and Medical Center, Kendall, Florida, United States
- Omega Research Orlando, LLC, Orlando, Florida, United States
- Augusta University, Augusta, Georgia, United States
- St. Paul Rheumatology, Eagan, Minnesota, United States
- Northwell Health, LLC PRIME, Lake Success, New York, United States
- Altoona Center for Clinical Research, P.C., Duncansville, Pennsylvania, United States
- Fundacion Respirar Consultorios Médicos Dr. Doreski, Buenos Aires, Argentina
- Hospital Cordoba, Córdoba, Argentina
- Hospital Italiano de La Plata, La Plata, Argentina
- Framingham Centro Medico, La Plata, Argentina
- Instituto Medico CER, Quilmes, Argentina
- UZ Leuven, Leuven, Belgium
- Enroll SpA, Santiago, Chile
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05695950 on ClinicalTrials.govOther trials for Dermatomyositis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07111065FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)National Institute of Environmental Health Sciences (NIEHS)
- ACTIVE NOT RECRUITINGNCT07531446Construction of a Clinico-Imaging Collaborative Diagnostic Model for Dermatomyositis Combined With Interstitial Lung Disease Based on PET/CT Imaging Features and Clinical ParametersRuijin Hospital
- RECRUITINGPHASE2, PHASE3NCT07160205Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)Restem, LLC.
- RECRUITINGNANCT07377058RCT of Tocilizumab for Anti-MDA5+DMPeking Union Medical College Hospital
- RECRUITINGNCT07345949Panniculitis in DermatomyositisUniversity Hospital, Strasbourg, France
- RECRUITINGPHASE2NCT06857240Topical Ruxolitinib Cream for Refractory Cutaneous DermatomyositisThe Cleveland Clinic
- RECRUITINGPHASE1NCT06919380Nebulized MSC-Exos for Anti-MDA5+ RP-ILD: Safety and Efficacy TrialLi Shiyue
- RECRUITINGPHASE2NCT06672822Intralesional Injection of STS in Treatment of CalcinosisRobyn T. Domsic, MD, MPH